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While the effectiveness of pulmonary rehabilitation (PR) in chronic obstructive pulmonary
disease (COPD) is well established, its effectiveness in the most severe category of COPD,
i.e. patients with chronic respiratory failure (CRF), is less well known.
Objective: To verify the effects of PR in patients with CRF, and compare the level of
improvement with PR in these patients to that of COPDs not affected by CRF.
Methods: A multi-centre study was carried out on COPD patients with versus without CRF.
The PR program included educational support, exercise training, and nutritional and
psychological counselling. Lung function, arterial gases, walk test (6MWT), dyspnoea (MRC;
BDI/TDI), and quality of life (MRF28; SGRQ) were evaluated.
Results: Thousand forty seven consecutive COPD inpatients (327 with CRF) were
evaluated. In patients with CRF all parameters improved after PR (0.001). Mean changes:
FEV1, 112ml; PaO2, 3.0mmHg; PaCO2, 3.3mmHg; 6MWT, 48m; MRC, 0.85 units; MRF28 total
score, 11.5 units. These changes were similar to those observed in patients without CRF.Elsevier Ltd. All rights reserved.
Salvatore Maugeri, IRCCS, Divisione di Pneumologia, Via revislate 13, 28010 Veruno (NO) Italy.
776.
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M. Carone et al.2448Conclusions: This study, featuring the largest cohort so far reported in the literature,
shows that PR is equally effective in the more severe COPD patients, i.e. those with CRF,
and supports the prescription of PR also in these patients.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) determines
high morbidity and mortality. To date, it represents the
fourth leading cause of death in Europe and the United
States,1,2 and by 2020 it will rank third.3 Pulmonary
rehabilitation (PR) is recognized as a cornerstone of COPD
treatment: it ameliorates symptoms and exercise capacity,
and constitutes one of the few ways of improving health
status.4 The growing interest in PR is testiﬁed by the fact
that major scientiﬁc societies have each published speciﬁc
guidelines on the subject.5–7 More recently, a joint state-
ment of the American Thoracic Society and the European
Respiratory Society on PR described patient assessment,
exercise training, education, nutritional support, and
psychosocial support as integral parts of PR.8 Expected
beneﬁts from PR are reduced dyspnoea level, improved
exercise tolerance, and maximized patients’ health-related
quality of life (HRQoL).5
Almost all the studies demonstrating the efﬁcacy of PR
have included COPD patients at various stages of the
disease, including subgroups of patients with severe COPD.
However, in these studies COPD patients with chronic
respiratory failure (CRF) were either excluded or they were
lumped together with other COPD patients without CRF.
Similarly, meta-analyses on PR9–11 either excluded studies
involving patients with CRF or included patients with severe
COPD without giving information on the presence or not of
CRF. Thus, none of the papers included in these meta-
analyses has focused explicitly on the efﬁcacy of PR in CRF.
On the other hand, over recent years it has become
increasingly evident that many patients enrolled in PR
programmes have severe COPD, mostly with CRF.
To verify whether a PR programme can improve the
outcome also in COPD patients with CRF, and to compare the
level of improvement in these patients to that of COPD
patients without CRF, we conducted a large multi-centre
observational study, the Maugeri Study. To the best of our
knowledge this is the ﬁrst study designed to test the
hypothesis that PR is effective also in severe COPD with CRF.
Methods
The ‘‘Salvatore Maugeri’’ Foundation Ethical Committee
approved the study (143CEC/2001). Patients gave their
informed consent to participate in the study.
The non-proﬁt ‘‘Salvatore Maugeri’’ Foundation is the
largest Italian institution (2052 beds) devoted to rehabilita-
tion. It numbers several institutes throughout Italy. In its
respiratory units common protocols for PR are applied, and
usually all activities are planned and coordinated by an
inter-institute Central Department. In seven of these units
(Campoli/Telese, Cassano Murge, Lumezzane/Gussago, Mon-
tescano, Pavia, Tradate, Veruno), over a period of 24 months(April 2001–April 2003), we collected data from 1130
consecutive inpatients with stable COPD (with or without
CRF) who underwent an inpatient PR program.
All patients were diagnosed with COPD according to GOLD
criteria.2
All patients were suffering from dyspnoea, reduced
exercise tolerance, muscle deconditioning or limitation of
daily-life activities, but were in stable clinical conditions.
Medical therapy had to be optimized before recruitment of
subjects. Patients suffering from acute exacerbation (i.e.
requiring antibiotics, oral/parenteral steroids or an increase
of oxygen or bronchodilators over the previous 4 weeks) and
patients with lack of motivation or poor compliance,
neuromuscular disorders, unstable angina, or recent (i.e.
o6 months) myocardial infarction were excluded from the
PR program. Patients were hospitalized and all the costs
were supported by the Italian National Health System.
CRF was deﬁned as a condition in which patients had an
arterial oxygen tension (PaO2) o60mmHg requiring long-
term oxygen therapy and/or arterial carbon dioxide tension
(PaCO2) 445mmHg.
12,13
Patients underwent a comprehensive PR programme
consisting of: (a) verbal inputs stressing the need for
adherence to therapy, (b) educational support, (c) exercise
training, and (d) a nutritional intervention and psychological
counselling, if needed. The rehabilitation program was
completely tailored to suit the needs of the individual.
According to guideline recommendations,5–7 the exercise
programme was also tailored to the individual and a group of
exercises was chosen for each patient5–7 according to their
ability to tolerate exercise and their disease severity (e.g.
some patients were prescribed cycling training, others
walking training; some patients needed also postural ex-
ercises, etc.). The programme consisted, on average, of ﬁve
supervised daily sessions per week of: (a) aerobic exercise
training (cycling, walking, or arm exercise), (b) respiratory
muscle training, (c) breathing exercise, (d) postural exercises,
and (e) upper- and lower-body muscle strength training
exercises. Exercises were graded, i.e. their intensity weekly
increased as the patient progressed in the programme.14
Patients with CRF were provided with ambulatory oxygen
during the exercise sessions. The exercise programme was
supervised by a chest physiotherapist.
The outcome measures were dyspnoea, exercise capacity
and HRQoL,6 which were measured in all patients together
with spirometry and blood gas analysis. All measurements
were assessed at admission and at the end of the PR
programme. Dyspnoea was assessed by the Medical Research
Council (MRC) dyspnoea scale15 and the baseline/transi-
tional dyspnoea index (BDI/TDI).16 Exercise capacity was
evaluated by means of the 6min walking test (6MWT).17
Health status—HRQoL was evaluated through the follow-
ing questionnaires18: all patients with CRF received the
Maugeri Respiratory Failure Questionnaire (MRF28)
19; pa-
tients without CRF were administered the St. George’s
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Table 1 Baseline characteristics (mean value7SD) of
the two groups of COPD patients.
Parameter CRF Non-CRF p-Value
Number 327 720
Males/females 251/76 604/116 0.008
Age (years) 69.677.9 68.978.8 NS
BMI (kg/m2) 27.275.7 26.675.5 NS
FVC (% predicted) 61.7716.4 74.5716.3 0.001
FEV1 (% predicted) 37.3714.3 48.6715.9 0.001
RV (% predicted) 154.1761.9 155.4753.8 NS
pH (units) 7.4270.04z 7.4370.03 0.01
PaO2 (mmHg) 53.776.1
z 71.277.9 0.001
PaCO2 (mmHg) 46.978.7
z 38.874.7 0.001
6MWT (m) 283.37106.2 360.27110.5 0.001
MRC 3.7571.16 3.2171.17 0.001
BDIy 4.0972.06 5.272.36 0.001
MRF28—Total score 53.7723.5 46.4723.7
y 0.01y
MRF28—Activity 64.1727.5 56.8727.3
y 0.04y
MRF28—Cognitive
function
58.9726.9 57.4727.7y NSy
MRF28—Invalidity 66.9728.0 63.5727.4
y 0.02y
SGRQ—Total score 38.8716.1J 41.1716.9 NSJ
SGRQ—Symptoms 53.0719.2J 49.6721.7 NSJ
SGRQ—Activity 52.6722.5J 52.7720.7 NSJ
SGRQ—Impact 27.2715.0J 32.7718.2 0.004J
COPD, chronic obstructive pulmonary disease; CRF, chronic
respiratory failure; BMI, body mass index; FVC, forced vital
capacity; FEV1, forced expiratory volume in the 1 s; RV,
residual volume; pH, hydrogen-ion concentration; PaO2,
arterial oxygen tension; PaCO2, arterial carbon dioxide
tension; 6MWT, 6-min walking test; MRC, Medical Research
Council dyspnoea scale; BDI, baseline dyspnoea index; MRF28,
Maugeri Foundation Respiratory Failure questionnaire; SGRQ,
St. George’s Respiratory Questionnaire.
Higher score indicates worse dyspnoea level.
yLower score indicates worse dyspnoea level.
zArterial blood was sampled whilst patients were breathing
room air.
yMRF28 was also tested in a subgroup (n ¼ 93) of COPD
patients without CRF for comparison (in italics).
JThe SGRQ was also tested in a subgroup (n ¼ 77) of COPD
patients with CRF for comparison (in italics).
Efﬁcacy of pulmonary rehabilitation in chronic respiratory failure (CRF) 2449Respiratory Questionnaire (SGRQ).20,21 To perform a com-
parison between groups and verify the questionnaires’
discriminative capacity and sensitivity to changes, a
randomly selected subgroup of 77 patients with CRF was
administered also the SGRQ, and a subgroup of 93 patients
without CRF was administered also the MRF28.
The MRF28 is the only questionnaire speciﬁcally designed
for CRF. It has been translated into: Czech, English (Canada,
UK, USA), French (Canada, Switzerland), German, Italian,
Japanese, Portuguese (Brazil), and Spanish. Its 28 items are
grouped around three speciﬁc factors: daily activity,
associated with disability in daily life due to breathlessness;
cognitive function, related to impaired cognitive function;
invalidity, related to the experience of social isolation or
dependency on others. The MRF28 total and subscale scores
range from 0% (best health status) to 100% (poorest health
status).19
Spirometry and arterial blood gas analysis were per-
formed according to guidelines.22,23 Arterial blood was
sampled whilst patients were breathing room air.
Statistical analysis
Descriptive statistics were performed for all the recorded
variables. Baseline characteristics between the two groups
(CRF versus non-CRF) were compared by means of unpaired
t-test. The efﬁcacy of PR was assessed by comparing the
difference in the evaluated parameters between baseline
and post-treatment data. A repeated measures analysis of
covariance (baseline level used as covariate) model was
applied to test both pre–post-treatment differences within
the two groups and trends over time between groups.
Results are shown as change between post-treatment and
baseline levels (D values). For SGRQ and MRF28 question-
naires, analyses were performed on the total as well as
subscale scores. Threshold for statistical signiﬁcance was set
at 0.05.
Results
Baseline characteristics
A total of 1130 consecutive COPD patients were recruited; 83
subjects dropped out during the rehabilitation programme.
Therefore, the sample for analysis consisted of 1047 patients,
of whom 327 patients (31.2%) were affected by CRF. Patients’
mean baseline characteristics are shown in Table 1.
Patients were in the 70-year age group and, on average,
overweight (body mass index (BMI) higher than 24.9). In
particular, the percentage of overweight patients was 63% in
the CRF group and 58.9% in the non-CRF group (p ¼ NS).
Patients in the CRF group were more impaired in terms of
airway obstruction (p ¼ 0.001), walked fewer meters during
the 6MWT (p ¼ 0.001) and were more dyspnoeic (p ¼ 0.001)
than patients in the non-CRF group.
In the CRF group the most compromised MRF28 scores
were Activity and Invalidity. Impairment in Cognitive
function, although present, was less important. In the non-
CRF group, the SGRQ Activity and Symptoms scores were
more impaired than the Impact score. Interestingly, in
the subgroups in which both questionnaires were assessedthe SGRQ did not show any difference between the two
groups apart from the Impact score, whereas the MRF28
showed more impaired scores in the CRF group, with the
exception of the Cognitive function score.
Apart from the prescription of long-term oxygen therapy
(LTOT), there was no substantial difference in the chronic
baseline prescription of pharmacologic therapy between the
two groups of patients.Effects of PR in the whole sample
The average duration of the PR programme was 2474 (SD)
days. At the end of PR, an improvement in dyspnoea (TDI
and MRC), exercise capacity (MRF28 and SGRQ), and
pulmonary function was found in all patients. In particular,
MRC improved (mean7SE) by 19.670.8%, walking distance
by 19.671.4%, MRF28 total score by 23.572.5%, SGRQ total
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M. Carone et al.2450score by 19.673.1%, and forced expiratory volume in 1 s
(FEV1) by 1470.9%. For all parameters the difference versus
baseline was statistically signiﬁcant (p ¼ 0.001).
Comparing the effects of PR in CRF and non-CRF
patients
Analysing data according to diagnostic groups, we found that
both groups showed very similar patterns (Table 2). FEV1
slightly improved; in the CRF group this improvement was on
average 112ml compared to 154ml in the non-CRF group
(p ¼ 0.03 between groups, p ¼ 0.001 versus baseline). The
improvement in PaO2 showed no difference between the two
groups: 3.0mmHg (p ¼ 0.01) in the CRF group and 2.2mmHg
(p ¼ 0.05) in the non-CRF group. PaCO2 decreased by
3.3mmHg in the CRF group (p ¼ 0.001) and by 0.4mmHg in
the non-CRF group (p ¼ NS) (p ¼ 0.001 between groups). The
distance walked during the 6MWT also showed a similar
improvement in the two groups, of 48.2m in the CRF and
47.8m in the non-CRF group (both p ¼ 0.001 versus baseline).
Dyspnoea was reduced in both groups after the PR
programme (p ¼ NS between groups). The MRC score
decreased by 0.85 and 0.73 units (both p ¼ 0.001), and TDI
was on average 3.68 and 3.78 in the CRF and non-CRF
groups, respectively.
Also health status improved after rehabilitation. In the
CRF group, all MRF28 scores improved, from a minimum of
5.2 units (Cognitive function) to a maximum of 17.6 units
(Activity). These improvements were highly signiﬁcantTable 2 Variation of the principal parameters after rehabilita
Parameter CRF
DFEV1 (ml) 11271.5
y
DPaO2 (mmHg) 3.070.31
y
DPaCO2 (mmHg)
 3.370.45y
D6MWT (m) 48.274.3y
DMRC 0.8570.06y
TDI 3.6870.15
DMRF28—Total score
,J 10.571.2
DMRF28—Activity
,J 15.471.7
DMRF28—Cognitive
,J 3.272.0
DMRF28—Invalidity
,J 7.071.6
DSGRQ—Total score,z 8.371.5
DSGRQ—Symptoms,z 19.472.8
DSGRQ—Activity,z 5.972.1
DSGRQ—Impact,z 5.971.4
COPD, chronic obstructive pulmonary disease; CRF, chronic respirator
forced expiratory volume in the 1 s; RV, residual volume; pH, hydr
arterial carbon dioxide tension; 6MWT, 6-min walking test; MRC, Me
index; MRF28, Maugeri Foundation Respiratory Failure questionnaire;
Reduction in score indicates improvement. For all other paramet
yp ¼ 0.001 versus baseline.
zp ¼ NS versus baseline.
yp ¼ 0.01 versus baseline.
zThe SGRQ was also tested in a subgroup (n ¼ 77) of COPD patien
JThe MRF28 was also tested in a subgroup (n ¼ 93) of COPD patien
All differences between pre- and post-treatment data are signiﬁ
interactions according to the ANOVA model have been shown for M
SGRQ—Activity (p ¼ 0.013), pointing out a more marked decrease in(Invalidity, Activity, and Total score, p ¼ 0.01; Cognitive
function, p ¼ 0.02) (Figure 1).
In patients without CRF the SGRQ total score and all
subscales (Symptoms, Activity, and Impact) showed a similar
behaviour to that of the MRF28 (Figure 2). All scores
statistically improved (p ¼ 0.001). For the Total and Impact
scores improvement was also clinically signiﬁcant, being
410units for the Total score and 48units for the Impact
score, well over the 4unit threshold for clinical signiﬁcance.24
As previously mentioned, the SGRQ was also administered
to a subgroup of 77 CRF patients, and the MRF28 to a
subgroup of 93 patients without CRF. No differences in SGRQ
were found between the two groups as the score decreased
by 11.270.6 units in the non-CRF group and by
8.171.5 units in the CRF group (p ¼ NS between groups).
Conversely, the improvement found in the MRF28 was
signiﬁcantly higher in the CRF than in the non-CRF group
(11.771.3 versus 5.171.3; p ¼ 0.001 between groups).
Discussion
The present study evaluated the effectiveness of a
comprehensive individually tailored PR programme in COPD
patients with CRF, comparing its effects in this group with
those in COPD patients not affected by CRF. Although it has
been reported that PaO2 and PaCO2 are factors unrelated to
the response to exercise training in COPD patients,25 there
has been little research on PR speciﬁcally targeted at CRF
patients and to the best of our knowledge this is the ﬁrsttion (mean value7S.E.).
Non-CRF Between groups, p-value
15471.3y 0.03
2.270.35y NS
0.470.20z 0.001
47.872.7y NS
0.7370.03y NS
3.7870.10 NS
5.171.3 0.002
4.671.8 0.001
4.873.2 NS
7.972.3 NS
11.170.6 NS
16.670.8 NS
12.070.8 0.007
8.470.7 NS
y failure; BMI, body mass index; FVC, forced vital capacity; FEV1,
ogen-ion concentration; PaO2, arterial oxygen tension; PaCO2,
dical Research Council dyspnoea scale; BDI, baseline dyspnoea
SGRQ, St. George’s Respiratory Questionnaire.
ers, increase in score indicates improvement.
ts with CRF for comparison (in italics).
ts without CRF for comparison (in italics).
cant, po0.001 except DMRF28—Cognitive (p ¼ 0.04). Signiﬁcant
RF28—Total score (p ¼ 0.014), MRF28—Activity (p ¼ 0.001) and
the CRF (MRF28) and non-CRF (SGRQ) groups, respectively.
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Figure 2 Improvement in SGRQ scores (patients without CRF) (mean value7SE) after PR programme.
Efﬁcacy of pulmonary rehabilitation in chronic respiratory failure (CRF) 2451study demonstrating, in a large cohort of 4300 of COPD
patients with CRF, that PR is effective also in this group.
Several meta-analyses have been published on PR.9–11
One of these excluded from the analysis studies with
patients requiring domiciliary oxygen.9 In the other two,
generic subgroups of patients with severe COPD are
described. However, none of the papers included in these
two meta-analyses speciﬁcally evaluated patients with CRF.
In some, in fact, patients were considered as very severe
simply on the basis of a low FEV1% predicted
26–28 or a high
score at the MRC scale29; in other papers, the real need for
O2 therapy (i.e. blood gas analysis or oxygen prescription)
was not described.30
A few other studies evaluated the effects of PR in very
severe COPD, i.e. patients at the extreme end of the disease
spectrum such as COPD patients on LTOT.31,32 However, in
these studies either the PaO2 was not reported
31 or the PR
programme consisted of just one single session per week.32
In our study all patients were hospitalized. Although in
the United States inpatient rehabilitation is usually reserved
for patients who are too disabled to travel to outpatient
settings,33 in Europe this is a quite common setting for
PR,33,34 and in Italy the National Health System routinely
reimburses all costs.Lung function
Although it is generally thought that PR should not change
the lung function of COPD patients, it has been reportedthat an individualized, graded PR programme can determine
an improvement in spirometry.31,35 Individualization and
gradation of the PR programme such as we adopted in our
protocol, rather than a uniform exercise protocol as is
usually applied in heterogeneous patient populations, could
therefore be a factor accounting for the improvement we
found in lung function.
Another possible explanation is based on treatment
compliance. Guidelines on PR state that stressing adherence
to therapy through an educational intervention1 should be a
component part of the program. During the rehabilitation
period, we stressed the need to adhere completely to the
prescribed therapy as well as to the program. This might be
one reason for the improvement we observed in both patient
groups, with and without CRF. Notably, the greater
improvement was observed in patients with CRF, indicating
that airﬂow limitation may be ameliorated also in patients
with more severe COPD.Exercise tolerance
The distance walked similarly increased in the two groups of
patients after PR, 17% in patients with CRF and 13% in COPD
patients without CRF. In this regard, the increment might
appear small, although not different between groups.
However, it is worth noting that, especially in such
compromised CRF subjects, also a little improvement may
be subjectively valuable.
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that the pooled effect size on 6MWT of the included
randomized controlled trials is 49m11 and a recent ‘‘State-
of-the-Art’’ review on PR4 showed that rehabilitation
programmes including more sessions are more effective
than programmes with fewer sessions (34.5m with o28
sessions versus 50.3m with 428 sessions). Consistent with
this evidence, a mean improvement of about 48m was found
in both groups, who on average received 24 rehabilitative
sessions. In addition, the percentage of patients who
improved their walking ability by at least 54m, i.e. the
threshold considered signiﬁcant for a clinically signiﬁcant
improvement after an intervention,36 was 39.6% in the CRF
group and 41.0% in the non-CRF group.
Symptoms
Dyspnoea was assessed by two different questionnaires. The
MRC scale is simple to administer and not time consuming;
however, it represents a unidimensional measure.16 Con-
versely, the BDI/TDI needs to be administered by an expert
operator but has multidimensional properties.16 The im-
provement in dyspnoea level as measured by these two
questionnaires was similar between the two groups of
patients, although the CRF group showed a slightly better
trend.
Quality of life
It is widely recognized that PR improves patients’ HRQoL.
We demonstrated that HRQoL improved also in the more
severe COPD group, i.e. patients with CRF. Although
measured by two different questionnaires, the pattern of
improvement found was similar in the two groups. More
interestingly, in the two subgroups that received both
questionnaires, the pattern of response to the SGRQ and
MRF28 between the two groups was different. At baseline,
the SGRQ was not able to differentiate between the two
groups, apart from the Impact score, whereas the MRF28
discriminated very well. After rehabilitation, we found no
difference in score variation as measured by the SGRQ,
apart from the Activity score. Conversely, the MRF28 showed
signiﬁcant differences in improvement between the two
groups of patients in both Total and Activity scores.
Similarly, Clini et al.37 applied the SGRQ and MRF28 to
compare the efﬁcacy of long-term non-invasive positive
pressure ventilation (NPPV) plus LTOT versus LTOT alone in
patients with COPD and CRF. In that study, the SGRQ did not
show any difference between the two groups, but the MRF28
appeared to be more speciﬁc and sensitive. At the end of the
2-year follow-up, patients on LTOT alone showed slightly
worsened health status scores, measured with the MRF28,
whereas patients who received LTOT and NIPPV had
improved scores.
Our ﬁndings together with Clini’s conﬁrm that for patients
with respiratory failure a condition-speciﬁc questionnaire
such as the MRF28 may be more appropriate than a disease-
speciﬁc questionnaire such as the SGRQ.
One possible limitation of the present study is that, in a
study designed to evaluate the effects of PR in CRF, there
was no control group of CRF patients who did not undergoPR. However, our scope in this study was to verify if PR could
have the same beneﬁt in CRF as in non-CRF COPD patients;
as a consequence, the COPD group without CRF constitutes
the control group against which we compared the efﬁcacy of
PR in patients with CRF. A further point to consider is that it
would have been non-ethical to deny PR to a subgroup of
COPD patients—given the well-established efﬁcacy of PR in
COPD—particularly in an institution completely devoted to
rehabilitation and with patients subsidized by the National
Health System.
In conclusion, the present study demonstrates, in the
largest cohort so far reported in the literature, that PR,
known to be effective in COPD in general, is also equally
effective in end-stage COPD, i.e. patients with CRF.
Conﬂict of interest
None of the authors have a conﬂict of interest to declare in
relation to this work.
Acknowledgements
The authors are extremely grateful to Prof. Ciro Rampulla
for his important contribution to statistical analysis, to Dr.
Giorgio Bertolotti for training the personnel that adminis-
tered the questionnaires, and to Ms. Rosemary Allpress for
revising the manuscript. The study was supported by a grant
from the Italian Ministry of Health (ICS 0030.8, N. 95).
References
1. Celli BR, MacNee W, Committee members. Standards for the
diagnosis and treatment of patients with COPD: a summary of
the ATS/ERS position paper. Eur Respir J 2004;23:932–46.
2. GOLD. Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease. NHLBI/WHO work-
shop report. Vol. Publication No. 2701. National Heart, Lung,
and Blood Institute, 2001.
3. World Health Organisation. WHO programme on management of
noncommunicable diseases. World Health Report, 2000.
4. Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary
rehabilitation in chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2005;172:19–38.
5. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel.
Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based
guidelines. Chest 1997;112:1363–96.
6. Donner CF, Muir JF. Selection criteria and programmes for
pulmonary rehabilitation in COPD patients. Rehabilitation and
Chronic Care Scientiﬁc Group of the European Respiratory
Society. Eur Respir J 1997;10:744–57.
7. American Thoracic Society. ATS statement: pulmonary rehabi-
litation—1999. Am J Respir Crit Care Med 1999;159:1666–82.
8. Nici L, Donner C, Wouters E, et al. American thoracic society/
European respiratory society statement on pulmonary rehabi-
litation. Am J Respir Crit Care Med 2006;173:1390–413.
9. Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of
respiratory rehabilitation in chronic obstructive pulmonary
disease. Lancet 1996;348:1115–9.
10. Salman GF, Mosler MC, Beasley BW, et al. Rehabilitation for
patients with chronic obstructive pulmonary disease. Meta-
analysis of randomized controlled trials. J Gen Intern Med
2003;18:213–21.
ARTICLE IN PRESS
Efﬁcacy of pulmonary rehabilitation in chronic respiratory failure (CRF) 245311. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary
rehabilitation for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2006;18(4):CD003793.
12. Pierson DJ. Respiratory failure: introduction and overview. In:
Pierson DJ, Kacmarek RM, editors. Foundation of respiratory
care. New York: Churchill Livingstone; 1992. p. 295–310.
13. Petty TL, Casaburi R, Burns MR. Recommendations of the ﬁfth
oxygen consensus conference. Respir Care 2000;45:957–61.
14. Maltais F, LeBlanc P, Jobin J, et al. Intensity of training and
physiologic adaptations in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 1997;155:555–61.
15. Fletcher CMC. Standardised questionnaire on respiratory
symptoms: a statement prepared and approved by the MRC
committee on the aetiology of chronic bronchitis (MRC breath-
lessness score). BMJ 1960;2:1665.
16. Mahler DA, Guyatt GH, Jones PW. Clinical measurements of
dyspnoea. New York: Marcel Dekker; 1998 (Mahler, DA, ed.
Dyspnoea).
17. ATS Statement. Guidelines for the six minute walk test. Am J
Respir Crit Care Med 2002;116:111–7.
18. Carone M, Jones PW. Health status (‘quality of life’). Eur Respir
Mon 2000;13:22–35.
19. Carone M, Bertolotti G, Anchisi F, et al. Analysis of factors that
characterize health impairment in patients with chronic
respiratory failure. Quality of life in chronic respiratory failure
group. Eur Respir J 1999;13(6):1293–300.
20. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete
measure for chronic airﬂow limitation—the St. George’s
respiratory questionnaire. Am Rev Respir Dis 1992;145:1321–7.
21. Carone M, Bertolotti G, Anchisi F, et al. Il St. George’s
respiratory questionnaire (SGRQ): la versione italiana. Rass
Pat App Respir 1997;14:31–7.
22. American Thoracic Society. Standardization of spirometry. 1994
update. Am J Respir Crit Care Med 1995;152:1107–36.
23. AARC Clinical Practice Guideline. Blood gas analysis and hemoxi-
metry: 2001 revision & update. Respir Care 2001;46:498–505.
24. Jones PW. Interpreting thresholds for a clinically signiﬁcant change
in health status in asthma and COPD. Eur Respir J 2002;19:398–404.
25. Decramer M. Treatment of chronic respiratory failure: lung
volume reduction surgery versus rehabilitation [review]. Eur
Respir J 2003;22:47s–56s.26. Goldstein RS, Gordt EH, Stubbing D, et al. Randomised
controlled trial of respiratory rehabilitation. Lancet 1994;344:
1394–7.
27. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient
rehabilitation of COPD: a randomized trial. Chest 2000;117:
976–83.
28. Engstrom CP, Persson LO, Larson S, et al. Long-term effects of a
pulmonary rehabilitation programme in outpatients with
chronic obstructive pulmonary disease: a randomized con-
trolled trial. Scand J Rehabil Med 1999;31:207–13.
29. Wedzicha JA, Bestall JC, Garod R, et al. Randomized controlled
trial of pulmonary rehabilitation in severe chronic obstructive
pulmonary disease patients stratiﬁed with the MRC dyspnoea
scale. Eur Respir J 1998;12:363–9.
30. Bush AJ, McClements JD. Effects of a supervised home exercise
program on patients with severe chronic obstructive pulmonary
disease. Phys Ther 1988;68:469–74.
31. Ngaage DL, Hasney K, Cowen ME. The functional impact of an
individualized, graded, outpatient pulmonary rehabilitation in
end-stage chronic obstructive pulmonary disease. Heart Lung
2004;33(6):381–9.
32. Faager G, Larsen FF. Performance changes for patients with
chronic obstructive pulmonary disease on long-term oxygen
therapy after physiotherapy. J Rehabil Med 2004;36:153–8.
33. Hill NS. Pulmonary rehabilitation. Proc Am Thorac Soc 2006;3:
66–74.
34. Kida K, Jinno S, Nomura K, et al. Pulmonary rehabilitation
program survey in North America, Europe and Tokyo.
J Cardiopulm Rehabil 1998;18:301–8.
35. Mercken EM, Hageman GJ, Schols AMWJ, et al. Rehabilitation
decreases exercise-induced oxidative stress in chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med 2005;172:
994–1001.
36. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH.
Interpreting small differences in functional status: the six
minute walk test in chronic lung disease patients. Am J Respir
Crit Care Med 1997;155:1278–82.
37. Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, et al.
The Italian multicentre study on noninvasive ventilation in
chronic obstructive pulmonary disease patients. Eur Respir J
2002;20:529–38.
